Results of Xarelto’s Clinical Trial Revealed

.

Results of Xarelto’s Clinical Trial Revealed

The results of clinical trials of Xarelto, a blood clot preventer drug, have been revealed. It has been informed that the drug has done far better in clinical trials as compared to the other medication which claims to prevent blood clots.

The drug Xarelto, which also has chemical name rivaroxaban, is a creation of Johnson & Johnson. During the clinical trial, about 5,000 patients were prescribed with the drug. The drug is not only effective in preventing blood clots, but is also safe to prescribe.

The manufacturer of the drug is of the view that in the coming time the drug might gain global recognition. Blood clots can cause serious health problems. They have the tendency of travelling to major organs like lung.

The clinical trial of the drug was led by Dr. Harry Buller. The results of the clinical trial were presented at American College of Cardiology during annual scientific sessions. While presenting the results, Dr. Harry said: “Rivaroxaban is just as good as standard treatment for pulmonary embolism -- these data are pretty convincing -- and this is an oral-only approach, which makes it very simple”.

While presenting the results, the results of other blood clotting preventers were also highlighted. Dr. Harry informed that about 1.1% of the patients taking Xarelto experienced major bleed as compared to 2.2% of the patients taking heparin and warfarin, blood clot preventer.

It has been informed that every year about 600,000 people succumbs to death in America because of blood clots. By introducing Xarelto for the clinical use, a large number of people could be saved from falling into the traps of death because of blood clots. Besides, Johnson & Johnson would also be able to add additional revenue of $500 million through the sales of Xarelto.


Latest News

Home Depot to Bid Farewell to Blake as   CEO But He Continues to Stay As Chairma
UPS Store Data Breach: About 100,000 or More Customers Could Have Been Affected
Target Feels Progress Lies Ahead But Trims Its Outlook For the Year
Bank of America to Settle Matters With Close to $17 Billon
Medical Device Tax to Support Obamacare Is Not Collecting as Much Cash as was Ex
Standard Chartered to Pay$300 Mln Penalty By Order of New York Regulators
In July Construction of  New Homes Grow to Eight Month High
Shares of Apple Hit a Record High Before Its New iPhone 6 Arrives
Google: Its Growth and Stature
A Survey Says 36% of Americans Have No Savings for Post Retirement Years
Former Co -owners and Two Employees of Rancho Feeding Corp. Charged with Felonie
Audit Report Says Illinois Overdrew Money From Federal Medicaid